Table 2.

Summary of the treatment strategies for adnexal and orbital involvement

Palpebral (lid) involvement
	n	Pattern	Treatment
Yaghoobi et al.[64]	9	CL	A
Mohammadpour et al.[65]	6	CL	D, C
Oliveira-Neto et al.[66]	5	CL	D
Hanafi et al.[67]	1	CL	A
Kaul et al.[68]	1	CL	A
Gupta[69]	1	CL	D
Doroodgar et al.[70]	1	CL	D
Doroodgar et al.[71]	1	CL	D
Duman et al.[72]	1	CL	D
Khaled et al.[73]	1	CL	D, H
Veraldi et al.[23]	1	CL	I
Jaouniet al.[20]	1	CL	C
Rahimi et al.[21]	1	CL	D
Vinetz et al.[74]	1	CL	D
Jafari et al.[75]	1	CL	D
Ozdemir et al.[16]	1	CL	G
O’Neill et al.[76]	1	CL	D
Morgan[22]	1	CL	D
Kiafar et al.[19]	1	DCL	F
Chaudhry et al.[77]	1	CL	H
Admassu et al.[18]	1	VL	D
Conjunctival involvement
El-Hassan et al.[36]	6	PKDL	D
Razeghinejad et al.[78]	1	DCL	E
Nikandish et al.[17]	1	CL	I, B
Kiafar et al.[19]	1	DCL	F
Mixed palpebral and conjunctival involvement
Satici et al.[15]	3	CL	NA
Prasad et al.[26]	1	VL	E
Chaudhry et al.[77]	1	CL	H
Admassu et al.[18]	1	VL	D

A=Intralesional pentavalent antimonial; B=Intralesional amphotericin B; C=Paromomycin ointment; D=Systemic pentavalent antimonial; E=Systemic Miltefosine; F=Systemic amphotericin B; G=Systemic allopurinol; H=Systemic azole; I=Surgical excision; NA=Not available